Astra Plots Post-Covid Future With $39 Billion Alexion Deal
(Bloomberg) -- AstraZeneca Plc, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a $39 billion deal for rare-disease specialist Alexion Pharmaceuticals Inc. Load Error The proposed cash-and-stock acquisition will add treatments for uncommon blood and immunological disorders to the portfolio of Cambridge, U.K.-based AstraZeneca, which had spent years paring away older and less profitable ...
Login to comment.